Drug Profile
Research programme: metabolic syndrome therapy - BioLineRx
Alternative Names: BL-2040Latest Information Update: 07 May 2007
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 26 Jul 2005 Preclinical trials in Metabolic syndrome in Israel (PO)